Published: 13 December 2018

Publications

Prescriber Update Quiz 2018 – Answers

This article is more than five years old. Some content may no longer be current.

Prescriber Update 39(4): 63
December 2018

1. How many puffs of Respigen (salbutamol) would you need to take to be exposed to the amount of alcohol that is present in 100 g of ripe banana?
   1. 1
   2. 10
   3. 100
   4. 1000
2. In which of the following patient groups is codeine a suitable option for pain relief?
   1. Breastfeeding mothers following Caesarean section.
   2. Children aged under 6 years following orthopaedic surgery.
   3. Children aged under 12 years following bowel surgery.
   4. Adolescents aged under 18 years following removal of tonsils or adenoids.
   5. None of the above.
3. As a CYP2D6 inhibitor, terbinafine may [increase / decrease] the plasma concentration (ie, the effect) of metoprolol.
4. What is the amount of active ingredient in the approved brands of tenofovir disoproxil in New Zealand?
   245mg
5. True or false: Opioid concentrations disappear immediately from the body after removal of a transdermal opioid patch.
6. Which products are currently being monitored by Medsafe because of a possible risk of neural tube defects when taken early in pregnancy?
   Tivicay and Triumeq
7. How do you reduce the risk of hypocalcaemia associated with zoledronic acid?
   1. Measure baseline serum calcium levels and treat pre-existing hypocalcaemia before administering zoledronic acid.
   2. Give adequate calcium and vitamin D to all patients receiving zoledronic acid.
   3. c) Monitor serum calcium levels and related metabolic parameters after starting zoledronic acid therapy.
   4. Be cautious when administering zoledronic acid with medicines known to cause hypocalcaemia.
   5. All of the above.
8. True or false: Febuxostat is not recommended in patients concomitantly treated with azathioprine or mercaptopurine.
9. What must a medical practitioner consider when arranging to administer a Section 29 medicine?
   1. The medicine must only be administered to a patient under their care.
   2. The medicine has not been evaluated by Medsafe for quality, safety and efficacy.
   3. They must seek informed consent from the patient.
   4. The supplier of the Section 29 medicine must hold information on the name of each patient who receives the unapproved medicine.
   5. All of the above.
10. A second dose of which medication may be needed to reverse the effects of dabigatran?
    Idarucizumab (Praxbind)